Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03-13

AUTHORS

A. Gökyer, A. Küçükarda, O. Köstek, M. B. Hacıoğlu, B. S. Sunal, N. C. Demircan, S. Uzunoğlu, S. Solak, K. İşsever, İ. Çiçin, B. Erdoğan

ABSTRACT

BACKGROUND: Sarcopenia is related to poor prognosis and drug toxicities in solid tumors. The aim of our study is to investigate the predisposition of patients with metastatic colorectal carcinoma who started regorafenib treatment to sarcopenia and prolonged survival. METHODS: Patients with metastatic colorectal carcinoma who receives regorafenib were search retrospectively. Dose-limiting toxicity was defined as dose reduction or toxicity requiring drug withdrawal. Sarcopenia evaluation was made with computed tomography performed within a month before treatment. Progression-free survival and overall survival were estimated. RESULTS: Thirty-six patients were found as suitable for the study. 63.9% of patients were found as basally sarcopenic. Dose-limiting toxicity occured 13 of 23 patients (56.5%) with basal sarcopenia, whereas only 1 of 13 patients (7.6%) with no sarcopenia exhibited dose-limiting toxicity (p = 0.005). Three patients suffered from grade 3-4 toxicity. Hand-foot syndrome, hypertension, and mucosal rash were the most seen side effects. Mean regorafenib treatment duration was 3.36 months. There was no significant difference in the progression-free survival (PFS) and the overall survival (OS) between sarcopenic patients and patients with no sarcopenia. Durations were as OS 24.2 weeks in patients with sarcopenia (95% CI 16.7-31.7), 28.1 weeks in patients with no sarcopenia (95% CI 20.5-35.7) (p = 0.36), and as PFS 14.2 weeks in patients with sarcopenia (95% CI 12.1-16.4), 14.8 weeks in patients with no sarcopenia (95% CI 9.7-20.1) (p = 0.65). CONCLUSION: Dose-limiting toxicity was significantly higher in basally sarcopenic patients who were started regorafenib as treatment of metastatic colorectal carcinoma. There was no significant relationship between overall survival and progression-free survival with sarcopenia. More... »

PAGES

1-6

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12094-019-02080-4

DOI

http://dx.doi.org/10.1007/s12094-019-02080-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112732059

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30868388


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "G\u00f6kyer", 
        "givenName": "A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00fc\u00e7\u00fckarda", 
        "givenName": "A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00f6stek", 
        "givenName": "O.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Department of Radiology, Trakya University School of Medicine, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hac\u0131o\u011flu", 
        "givenName": "M. B.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Department of Radiology, Trakya University School of Medicine, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sunal", 
        "givenName": "B. S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Demircan", 
        "givenName": "N. C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uzuno\u011flu", 
        "givenName": "S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Department of Radiology, Trakya University School of Medicine, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Solak", 
        "givenName": "S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sakarya University", 
          "id": "https://www.grid.ac/institutes/grid.49746.38", 
          "name": [
            "Department of Internal Medicine, Sakarya University School of Medicine, Sakarya, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "\u0130\u015fsever", 
        "givenName": "K.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "\u00c7i\u00e7in", 
        "givenName": "\u0130.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Erdo\u011fan", 
        "givenName": "B.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.2013.58", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000012185", 
          "https://doi.org/10.1038/bjc.2013.58"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/wvn.12147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009056940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.juro.2015.08.071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020031584"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)61900-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020430219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2015.12.030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022644363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp605", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039975559"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1152/jappl.1998.85.1.115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083287696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-017-3873-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091770018", 
          "https://doi.org/10.1007/s00520-017-3873-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000484950", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099627593"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000484950", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099627593"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21442", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100164642"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clcc.2018.02.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101146365"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clcc.2018.02.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101146365"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/2050640618781188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104340003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/2050640618781188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104340003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/md.0000000000013363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110323409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/md.0000000000013363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110323409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/md.0000000000013363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110323409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/md.0000000000013363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110323409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/md.0000000000013363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110323409"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03-13", 
    "datePublishedReg": "2019-03-13", 
    "description": "BACKGROUND: Sarcopenia is related to poor prognosis and drug toxicities in solid tumors. The aim of our study is to investigate the predisposition of patients with metastatic colorectal carcinoma who started regorafenib treatment to sarcopenia and prolonged survival.\nMETHODS: Patients with metastatic colorectal carcinoma who receives regorafenib were search retrospectively. Dose-limiting toxicity was defined as dose reduction or toxicity requiring drug withdrawal. Sarcopenia evaluation was made with computed tomography performed within a month before treatment. Progression-free survival and overall survival were estimated.\nRESULTS: Thirty-six patients were found as suitable for the study. 63.9% of patients were found as basally sarcopenic. Dose-limiting toxicity occured 13 of 23 patients (56.5%) with basal sarcopenia, whereas only 1 of 13 patients (7.6%) with no sarcopenia exhibited dose-limiting toxicity (p\u2009=\u20090.005). Three patients suffered from grade 3-4 toxicity. Hand-foot syndrome, hypertension, and mucosal rash were the most seen side effects. Mean regorafenib treatment duration was 3.36\u00a0months. There was no significant difference in the progression-free survival (PFS) and the overall survival (OS) between sarcopenic patients and patients with no sarcopenia. Durations were as OS 24.2\u00a0weeks in patients with sarcopenia (95% CI 16.7-31.7), 28.1\u00a0weeks in patients with no sarcopenia (95% CI 20.5-35.7) (p\u2009=\u20090.36), and as PFS 14.2\u00a0weeks in patients with sarcopenia (95% CI 12.1-16.4), 14.8\u00a0weeks in patients with no sarcopenia (95% CI 9.7-20.1) (p\u2009=\u20090.65).\nCONCLUSION: Dose-limiting toxicity was significantly higher in basally sarcopenic patients who were started regorafenib as treatment of metastatic colorectal carcinoma. There was no significant relationship between overall survival and progression-free survival with sarcopenia.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12094-019-02080-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1035367", 
        "issn": [
          "1699-048X", 
          "1699-3055"
        ], 
        "name": "Clinical and Translational Oncology", 
        "type": "Periodical"
      }
    ], 
    "name": "Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib", 
    "pagination": "1-6", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "06e72b8fd6d636ac3e22b351b293b05369427f9ab5b4cbd819f04a5bbca55a2d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30868388"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101247119"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12094-019-02080-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112732059"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12094-019-02080-4", 
      "https://app.dimensions.ai/details/publication/pub.1112732059"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000358_0000000358/records_127448_00000011.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs12094-019-02080-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12094-019-02080-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12094-019-02080-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12094-019-02080-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12094-019-02080-4'


 

This table displays all metadata directly associated to this object as RDF triples.

167 TRIPLES      21 PREDICATES      39 URIs      18 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12094-019-02080-4 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Ne4b676c6903b4b608868bea9acd93b35
4 schema:citation sg:pub.10.1007/s00520-017-3873-7
5 sg:pub.10.1038/bjc.2013.58
6 https://doi.org/10.1016/j.clcc.2018.02.005
7 https://doi.org/10.1016/j.ejca.2015.12.030
8 https://doi.org/10.1016/j.juro.2015.08.071
9 https://doi.org/10.1016/s0140-6736(12)61900-x
10 https://doi.org/10.1093/annonc/mdp605
11 https://doi.org/10.1097/md.0000000000013363
12 https://doi.org/10.1111/wvn.12147
13 https://doi.org/10.1152/jappl.1998.85.1.115
14 https://doi.org/10.1159/000484950
15 https://doi.org/10.1177/2050640618781188
16 https://doi.org/10.3322/caac.21442
17 schema:datePublished 2019-03-13
18 schema:datePublishedReg 2019-03-13
19 schema:description BACKGROUND: Sarcopenia is related to poor prognosis and drug toxicities in solid tumors. The aim of our study is to investigate the predisposition of patients with metastatic colorectal carcinoma who started regorafenib treatment to sarcopenia and prolonged survival. METHODS: Patients with metastatic colorectal carcinoma who receives regorafenib were search retrospectively. Dose-limiting toxicity was defined as dose reduction or toxicity requiring drug withdrawal. Sarcopenia evaluation was made with computed tomography performed within a month before treatment. Progression-free survival and overall survival were estimated. RESULTS: Thirty-six patients were found as suitable for the study. 63.9% of patients were found as basally sarcopenic. Dose-limiting toxicity occured 13 of 23 patients (56.5%) with basal sarcopenia, whereas only 1 of 13 patients (7.6%) with no sarcopenia exhibited dose-limiting toxicity (p = 0.005). Three patients suffered from grade 3-4 toxicity. Hand-foot syndrome, hypertension, and mucosal rash were the most seen side effects. Mean regorafenib treatment duration was 3.36 months. There was no significant difference in the progression-free survival (PFS) and the overall survival (OS) between sarcopenic patients and patients with no sarcopenia. Durations were as OS 24.2 weeks in patients with sarcopenia (95% CI 16.7-31.7), 28.1 weeks in patients with no sarcopenia (95% CI 20.5-35.7) (p = 0.36), and as PFS 14.2 weeks in patients with sarcopenia (95% CI 12.1-16.4), 14.8 weeks in patients with no sarcopenia (95% CI 9.7-20.1) (p = 0.65). CONCLUSION: Dose-limiting toxicity was significantly higher in basally sarcopenic patients who were started regorafenib as treatment of metastatic colorectal carcinoma. There was no significant relationship between overall survival and progression-free survival with sarcopenia.
20 schema:genre research_article
21 schema:inLanguage en
22 schema:isAccessibleForFree false
23 schema:isPartOf sg:journal.1035367
24 schema:name Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib
25 schema:pagination 1-6
26 schema:productId N11e45f0892b245528541031b56645ebd
27 N1e8033a28db3432192135d65b701b651
28 N4b32ebda462b4502819953dc59b09395
29 N4c38afcd09a84b2d80960bbf519d8add
30 N62b0edcf59a34bc5b057cebcaf86ef1a
31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112732059
32 https://doi.org/10.1007/s12094-019-02080-4
33 schema:sdDatePublished 2019-04-11T11:43
34 schema:sdLicense https://scigraph.springernature.com/explorer/license/
35 schema:sdPublisher N310c0870c070473c9bf0d7b18211731f
36 schema:url https://link.springer.com/10.1007%2Fs12094-019-02080-4
37 sgo:license sg:explorer/license/
38 sgo:sdDataset articles
39 rdf:type schema:ScholarlyArticle
40 N0319657504f94054b399f73d6b0706ea schema:affiliation https://www.grid.ac/institutes/grid.411693.8
41 schema:familyName Solak
42 schema:givenName S.
43 rdf:type schema:Person
44 N0c57e00a55ab42efb0d344974bea6343 rdf:first Ncbdbb4d09d304853b6a09e068e4cff63
45 rdf:rest N11b4c0da53254a63bd50501eff6d5986
46 N11b4c0da53254a63bd50501eff6d5986 rdf:first Nef9775d319ee4f8b85b6c33b573973cd
47 rdf:rest Nb2e8b0d6f2d540668aff2ee7c5acf02d
48 N11e45f0892b245528541031b56645ebd schema:name nlm_unique_id
49 schema:value 101247119
50 rdf:type schema:PropertyValue
51 N1e8033a28db3432192135d65b701b651 schema:name doi
52 schema:value 10.1007/s12094-019-02080-4
53 rdf:type schema:PropertyValue
54 N310c0870c070473c9bf0d7b18211731f schema:name Springer Nature - SN SciGraph project
55 rdf:type schema:Organization
56 N3ad59be74f13493185cb7fd19a1bc1a6 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
57 schema:familyName Çiçin
58 schema:givenName İ.
59 rdf:type schema:Person
60 N3e2eaebf1bee414c9f50adf8de352aef schema:affiliation https://www.grid.ac/institutes/grid.411693.8
61 schema:familyName Hacıoğlu
62 schema:givenName M. B.
63 rdf:type schema:Person
64 N43147f9348ea4ebcbe827af6e992abe6 rdf:first Nedae387637a74bbcba64a046e7beb3e5
65 rdf:rest Nadc150058b534eb082874f4e565cd2a7
66 N489e74442c7d4c88a49203e7b2129683 rdf:first N0319657504f94054b399f73d6b0706ea
67 rdf:rest Nfeb57801c87b4b7fad3fb10574fd3af8
68 N4b32ebda462b4502819953dc59b09395 schema:name readcube_id
69 schema:value 06e72b8fd6d636ac3e22b351b293b05369427f9ab5b4cbd819f04a5bbca55a2d
70 rdf:type schema:PropertyValue
71 N4c38afcd09a84b2d80960bbf519d8add schema:name dimensions_id
72 schema:value pub.1112732059
73 rdf:type schema:PropertyValue
74 N5ee71e312ea84bf68a744c80b9518ffd rdf:first N8e571f3bbfd54fdfb131b4b7f90d3c0b
75 rdf:rest N489e74442c7d4c88a49203e7b2129683
76 N62b0edcf59a34bc5b057cebcaf86ef1a schema:name pubmed_id
77 schema:value 30868388
78 rdf:type schema:PropertyValue
79 N77a7fdb8dece4bdf9361981c278705e6 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
80 schema:familyName Demircan
81 schema:givenName N. C.
82 rdf:type schema:Person
83 N8e571f3bbfd54fdfb131b4b7f90d3c0b schema:affiliation https://www.grid.ac/institutes/grid.411693.8
84 schema:familyName Uzunoğlu
85 schema:givenName S.
86 rdf:type schema:Person
87 Nadc150058b534eb082874f4e565cd2a7 rdf:first N77a7fdb8dece4bdf9361981c278705e6
88 rdf:rest N5ee71e312ea84bf68a744c80b9518ffd
89 Nb2e8b0d6f2d540668aff2ee7c5acf02d rdf:first N3e2eaebf1bee414c9f50adf8de352aef
90 rdf:rest N43147f9348ea4ebcbe827af6e992abe6
91 Ncbdbb4d09d304853b6a09e068e4cff63 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
92 schema:familyName Küçükarda
93 schema:givenName A.
94 rdf:type schema:Person
95 Ncd75cf3e1e724ee78f9b3f256ecf6e03 rdf:first N3ad59be74f13493185cb7fd19a1bc1a6
96 rdf:rest Ne03820e5b7864ad8bb3fb13ff13a10ec
97 Ne03820e5b7864ad8bb3fb13ff13a10ec rdf:first Nf8fa3ae02e8246f793c3b1bca35bd326
98 rdf:rest rdf:nil
99 Ne4b676c6903b4b608868bea9acd93b35 rdf:first Ne646d90003764e609ccd6289cbdce5aa
100 rdf:rest N0c57e00a55ab42efb0d344974bea6343
101 Ne646d90003764e609ccd6289cbdce5aa schema:affiliation https://www.grid.ac/institutes/grid.411693.8
102 schema:familyName Gökyer
103 schema:givenName A.
104 rdf:type schema:Person
105 Ned01a805a16e4f39b4e784d8a2863400 schema:affiliation https://www.grid.ac/institutes/grid.49746.38
106 schema:familyName İşsever
107 schema:givenName K.
108 rdf:type schema:Person
109 Nedae387637a74bbcba64a046e7beb3e5 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
110 schema:familyName Sunal
111 schema:givenName B. S.
112 rdf:type schema:Person
113 Nef9775d319ee4f8b85b6c33b573973cd schema:affiliation https://www.grid.ac/institutes/grid.411693.8
114 schema:familyName Köstek
115 schema:givenName O.
116 rdf:type schema:Person
117 Nf8fa3ae02e8246f793c3b1bca35bd326 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
118 schema:familyName Erdoğan
119 schema:givenName B.
120 rdf:type schema:Person
121 Nfeb57801c87b4b7fad3fb10574fd3af8 rdf:first Ned01a805a16e4f39b4e784d8a2863400
122 rdf:rest Ncd75cf3e1e724ee78f9b3f256ecf6e03
123 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
124 schema:name Medical and Health Sciences
125 rdf:type schema:DefinedTerm
126 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
127 schema:name Oncology and Carcinogenesis
128 rdf:type schema:DefinedTerm
129 sg:journal.1035367 schema:issn 1699-048X
130 1699-3055
131 schema:name Clinical and Translational Oncology
132 rdf:type schema:Periodical
133 sg:pub.10.1007/s00520-017-3873-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091770018
134 https://doi.org/10.1007/s00520-017-3873-7
135 rdf:type schema:CreativeWork
136 sg:pub.10.1038/bjc.2013.58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000012185
137 https://doi.org/10.1038/bjc.2013.58
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1016/j.clcc.2018.02.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101146365
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1016/j.ejca.2015.12.030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022644363
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1016/j.juro.2015.08.071 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020031584
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1016/s0140-6736(12)61900-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1020430219
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1093/annonc/mdp605 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039975559
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1097/md.0000000000013363 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110323409
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1111/wvn.12147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009056940
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1152/jappl.1998.85.1.115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083287696
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1159/000484950 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099627593
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1177/2050640618781188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104340003
158 rdf:type schema:CreativeWork
159 https://doi.org/10.3322/caac.21442 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100164642
160 rdf:type schema:CreativeWork
161 https://www.grid.ac/institutes/grid.411693.8 schema:alternateName Trakya University
162 schema:name Department of Radiology, Trakya University School of Medicine, Edirne, Turkey
163 Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey
164 rdf:type schema:Organization
165 https://www.grid.ac/institutes/grid.49746.38 schema:alternateName Sakarya University
166 schema:name Department of Internal Medicine, Sakarya University School of Medicine, Sakarya, Turkey
167 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...